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Convalescent plasma is a promising 
therapeutic strategy that might have 
benefit in patients with COVID-19,1,2 
despite unproven safety and efficacy. 
Although randomised clinical trials are 
ongoing, decision making with regard 
to the transfusion of convalescent 
plasma from patients who have 
recovered from COVID-19 should follow 
a risk-based approach, whereby the 
potential risks are minimised in favour 
of not yet proven therapeutic benefits. 
WHO Blood Regulators Network 
and several other stakeholders, 
such as the International Society of 
Blood Transfusion, recommend risk 
mitigation for transfusion-trans-
missible disease through pathogen 
inactivation.3,4 However, at present 
no data exist regarding the effect of 
pathogen-inactivation methods or 
cryopreservation on the stability of 
severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) neutral-
ising antibodies. 
We therefore analysed the effect of 
psoralen and ultraviolet light pathogen 
inactivation (Intercept Blood System; 
Cerus, Concord, CA USA) on the total 
SARS-CoV-2 IgG titre (IgG ELISA; 
Euroimmun, Lubeck, Germany) and 
neutralising capacity (life virus assay)5 
in convalescent plasma obtained 
from patients who have recovered 
from COVID-19. Our data show that 
pathogen inactivation of convalescent 
plasma does not impair the stability 
and neutralising capacity of SARS-
CoV-2-specific antibodies compared 
with non-pathogen-inactivated 
controls. Although SARS-CoV-2 IgG 
titre and neutralising capacity seem 
to correlate, initial observations from 
our ongoing convalescent plasma 
programme at University Hospital 
Carl-Gustav Carus (Dresden, Germany) 
have shown that some individual 
cases have moderate neutralising 
capacity despite high anti-SARS-
CoV-2-IgG titres (appendix). The 
stability of SARS-CoV-2 IgG and the 
overall neutralising capacity was also 
preserved at 100% when the plasma 
was shock frozen at –30°C after 
pathogen-inactivation (appendix) or 
stored as liquid plasma for up to 9 days 
(data not shown). 
Our data suggest that pathogen-
inactivation of convalescent plasma 
from patients who have recovered 
from COVID-19 does not alter the 
potential therapeutic potency and 
should be recommended to mitigate 
the risk for transfusion associated 
viral transmission. Considering the 
currently unproven clinical benefit of 
convalescent plasma obtained from 
patients who have had COVID-19, a 
shift in the risk–benefit ratio towards 
benefit by means of pathogen-
inactivation should be employed in 
all cases, in settings where the use of 
pathogen inactivation methods are 
available and established.
See Online for appendix
